Dr. Donald T. Weed, MD

Dr. Weed practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Weed's NPI, 1972537348, was assigned on July 10, 2006. Dr. Weed graduated from Vanderbilt University School Of Medicine in 1989. Dr. Weed holds Florida license ME70925.

Dr. Weed's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Weed's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Weed to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Weed practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Weed's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Weed is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Weed's licenses on file in 2 states: Florida and Tennessee.

Dmand AI lists endoscopic sinus surgery, larynx and vocal cord disease and thyroid surgery among the conditions Dr. Weed treats.

CMS data shows 589 Medicare services from Dr. Weed across 5 procedure codes in 2024, for 266 Medicare patients. Medicare paid $37,805 for them.

CMS counts 266 Medicare patients who saw Dr. Weed in 2024. The largest group is 65 to 74, with 117 patients. 75% of them have high cholesterol, and 68% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Weed's median patient age at 71, with 42% women.

In 2024, Dr. Weed wrote 204 Medicare Part D claims for 70 patients. 82% of them were for generic drugs. CMS names the drug for 99 of them, across 4 drugs with 11 or more claims each, at $643 in total drug cost. In 2023, CMS named 62 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Weed for performance year 2024, reported as part of a group. Dr. Weed accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Weed as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Spinal fusion: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 79 papers to Dr. Weed, published from 2008 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Biomarkers, Tumor. Dr. Weed has published most often in Head Neck. Dr. Weed's most frequent co-authors are Francisco J. Civantos, MD, Zoukaa B. Sargi, MD and David J. Arnold, MD.

Dmand AI links Dr. Weed to 3 clinical trials. Conditions studied include Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck and Neoplasms, Squamous Cell.

CMS Open Payments shows 55 general payments to Dr. Weed from 5 drug and device companies from 2017 to 2025. Education make up the largest share, 41% of the total. Intuitive Surgical, Inc. paid the most, $4,420.

Dmand AI lists 5 awards for Dr. Weed, most recently CMS Stage 1 EHR in 2013.

Dr. Weed graduated from Vanderbilt University School Of Medicine in 1989. Dr. Weed is a member of NHS and ACS.

Dr. Weed is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.